At EverHealth, we aim to bring patients evidence-based tools that meaningfully improve metabolic health, longevity, and disease prevention. Retatrutide sometimes shortened to RETA is the most potent peptide studied to date for lowering visceral fat, improving insulin signaling, and supporting healthier body composition. Early research published in The New England Journal of Medicine and Nature Medicine shows that retatrutide produces some of the strongest weight and metabolic improvements seen so far.
Retatrutide is not just another weight loss medication.
It works on multiple hormonal pathways that affect appetite, insulin response, energy use, and inflammation. For many patients, this opens the door to a broader improvement in metabolic function.
What is Retatrutide?
Retatrutide is an investigational, once-weekly injectable medication that activates GLP-1, GIP, and glucagon receptors at the same time. This triple-agonist design is central to why retatrutide has produced such large changes in clinical studies.
In phase-2 trials, retatrutide led to some of the largest improvements reported in both obesity and type 2 diabetes studies.
How Retatrutide Works
GLP-1: Promotes earlier and longer satiety and lowers post-meal glucose levels.
GIP: Further enhances insulin’s effect and contributes to fullness.
Glucagon: Slightly increases caloric expenditure and may shift the body toward using visceral fat for energy.
Together, these effects reduce intake while increasing expenditure, creating a stronger metabolic impact than GLP-1 therapies alone.
Expected Benefits
- Weight
In a 48-week NEJM study in adults with obesity, average weight change at higher doses ranged from −22.8 percent to −24.2 percent. Patients with type 2 diabetes also saw meaningful reductions in glucose and weight.
- Liver Fat
A 2024 Nature Medicine substudy in patients with MASLD/MASH showed notable reductions in liver fat by week 24. This supports retatrutide’s potential role in reducing long-term cardiometabolic and liver-related risks.
- Cardiometabolic Risk
Across trials, retatrutide improved glycemia and other cardiometabolic markers that closely track with long-term vascular risk.
Visceral Fat, Longevity, and Cancer-Related Risk
Visceral adipose tissue (VAT) drives inflammation, insulin resistance, lipid abnormalities, and vascular aging. Reducing VAT is associated with healthier metabolic aging and lower risk over time.
Research from the National Cancer Institute highlights several biological pathways linking central adiposity to cancer development, including chronic inflammation, insulin and growth-factor signaling, and hormonal changes.
Large epidemiologic analyses continue to show that visceral adiposity is more strongly associated with obesity-related cancers such as colorectal, post-menopausal breast, pancreatic, and liver cancers than overall weight alone.
While we do not yet have randomized trials showing retatrutide reduces cancer events, the connection between VAT and cancer biology provides a clear rationale for targeting visceral fat when appropriate.
Body Composition: Muscle Preservation While Losing Fat
All highly effective weight-loss medications reduce both fat mass and some lean mass. Across GLP-1 based therapies, about 25 to 40 percent of lost weight may come from lean mass unless steps are taken to protect it.
Early retatrutide body-composition data in type 2 diabetes suggest that fat loss exceeds lean loss and that the pattern is similar to other modern agents. This is reassuring, but muscle preservation still requires attention.
How We Maintain Muscle While Using Retatrutide
Protein: Usually 1.6 to 2.2 g/kg/day, adjusted to lean mass and kidney function.
Training: Progressive resistance training three to four days per week, along with zone-2 aerobic work.
DEXA Tracking: Baseline scan, then every 8 to 12 weeks to confirm decreases in fat mass and maintenance or improvement in ALMI.
Micronutrients: Creatine, vitamin D (if low), and adequate electrolytes.
Safety Profile
Common symptoms include nausea, early fullness, reflux, and constipation. These are generally dose-dependent and improve with slower titration.
Less common effects include mild heart rate increases, constipation, or small ALT elevations.
Serious but uncommon issues include gallbladder complications or pancreatitis. As with other GLP-1 agents, rodent studies showed a signal for thyroid C-cell tumors, but this has not been confirmed in humans. We avoid retatrutide in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Phase-2 safety data have been consistent with other incretin-based therapies.
Who May Be a Good Candidate
Retatrutide may be considered for patients with:
-
Central or visceral obesity
-
Metabolic syndrome
-
Prediabetes or type 2 diabetes
-
Elevated liver fat or MASLD risk
-
Hypertension or dyslipidemia related to weight
-
Inadequate response to lifestyle changes or prior GLP-1 therapy
Candidacy is always individualized after a complete clinical review.
How We Prescribe and Monitor Retatrutide at EverHealth
Baseline:
Comprehensive labs (A1c, CMP, lipids, hs-CRP), DEXA body composition including visceral fat and ALMI, blood pressure, and liver stiffness or PDFF when indicated.
Dosing:
Once-weekly injection with a gradual dose increase to minimize GI effects. The exact regimen depends on tolerance and treatment goals.
Follow-up:
Visits around weeks 4, 8, and 12, then every 8 to 12 weeks. We review nutrition, training, dose adjustments, symptoms, DEXA changes, and metabolic markers.
Targets:
-
Steady visceral fat reduction
-
Maintenance or improvement of ALMI
-
A1c, triglycerides, ApoB, and liver fat trending in the right direction
Take-Home Message
Retatrutide combines large, durable reductions in weight and visceral fat with improvements in liver fat and other metabolic markers. When paired with resistance training, structured nutrition, and DEXA-based monitoring, it supports healthier metabolic aging and long-term risk reduction.
Scientific Sources
